Arovella Newsletter December 2022
Hello and welcome again to our quarterly reach out. It’s designed to give you a glimpse of the behind-the-scenes activity on how we are bringing your company to the fore in the competitive battleground that is oncology. We are pleased indeed to tell you that we are just where we want to be and our work on ALA101 has, as you would be aware, led us to a collaboration with one of the country’s foremost oncology driven companies, Imugene Ltd.
Quarterly highlights:
Imugene and Arovella entered into a Strategic Collaboration to combine ALA-101 and Imugene’s onCARlytics
Arovella received notice that its European patent for the iNKT cell platform will proceed to grant
Arovella received $1.05 million through the R&D tax rebate
Dr. Michael Baker
CEO AND MD
